ALK and neuroblastoma: Nevertheless, for the systemic administration of RNAi molecules, the main challenge remains the delivery system and to date the knockdown of ALK expression has been successfully employed in pre-clinical models of NB only using NB-targeted liposomes to entrap ALK-directed siRNAs, either alone [15,254] or in combination with an ALK inhibitor [255].